KR100847346B1 - 여성 성기능장애를 치료하기 위한 방법 및 제제 - Google Patents

여성 성기능장애를 치료하기 위한 방법 및 제제 Download PDF

Info

Publication number
KR100847346B1
KR100847346B1 KR1020037008338A KR20037008338A KR100847346B1 KR 100847346 B1 KR100847346 B1 KR 100847346B1 KR 1020037008338 A KR1020037008338 A KR 1020037008338A KR 20037008338 A KR20037008338 A KR 20037008338A KR 100847346 B1 KR100847346 B1 KR 100847346B1
Authority
KR
South Korea
Prior art keywords
therapeutically effective
compound
effective amount
delete delete
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037008338A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007427A (ko
Inventor
레오나드토마스더블유.
웰던알.포레스트
Original Assignee
바 래버러토리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바 래버러토리즈, 인코포레이티드 filed Critical 바 래버러토리즈, 인코포레이티드
Publication of KR20040007427A publication Critical patent/KR20040007427A/ko
Application granted granted Critical
Publication of KR100847346B1 publication Critical patent/KR100847346B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020037008338A 2000-12-22 2001-12-21 여성 성기능장애를 치료하기 위한 방법 및 제제 Expired - Fee Related KR100847346B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25774500P 2000-12-22 2000-12-22
US60/257,745 2000-12-22
PCT/US2001/049978 WO2002051420A2 (en) 2000-12-22 2001-12-21 Methods and formulations for the treatment of female sexual dysfunction

Publications (2)

Publication Number Publication Date
KR20040007427A KR20040007427A (ko) 2004-01-24
KR100847346B1 true KR100847346B1 (ko) 2008-07-21

Family

ID=22977570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037008338A Expired - Fee Related KR100847346B1 (ko) 2000-12-22 2001-12-21 여성 성기능장애를 치료하기 위한 방법 및 제제

Country Status (11)

Country Link
US (2) US20020107230A1 (enExample)
EP (2) EP1862167A3 (enExample)
JP (1) JP4945052B2 (enExample)
KR (1) KR100847346B1 (enExample)
AT (1) ATE370737T1 (enExample)
AU (1) AU2002232759B2 (enExample)
CA (1) CA2431834C (enExample)
DE (1) DE60130147T2 (enExample)
ES (1) ES2292637T3 (enExample)
MX (1) MXPA03005741A (enExample)
WO (1) WO2002051420A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102483A3 (en) * 1998-06-11 2002-11-28 Endorech Inc Sainte Foy Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
TW200404551A (en) * 2002-05-17 2004-04-01 Wyeth Corp Hormone replacement therapy
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
RS52945B (sr) 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
MX368189B (es) 2004-10-20 2019-09-23 Endorecherche Inc Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
CA2644652A1 (en) * 2005-03-02 2006-09-08 Nascent Pharmaceuticals, Inc. Combinaion therapy for topical application in the treatment of dry eye syndrome
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
AU2006278866B2 (en) * 2005-07-25 2012-03-15 Lek Pharmaceuticals D.D. Process for the preparation of crystalline perindopril
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1971325A2 (en) * 2005-12-27 2008-09-24 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US20210024636A1 (en) * 2019-07-26 2021-01-28 Chemistryrx Compositions and methods for treating sexual dysfunction
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7506407A (nl) * 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6046240A (en) * 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction
US5891915A (en) * 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6001845A (en) * 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6083956A (en) * 1998-11-20 2000-07-04 Pfizer Inc. Optically pure androgen mediator
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
국제공개특허공보 제99-21562호(1999.5.6.공개)*
미국특허공보 제6117446호(2000.9.12.공개)*

Also Published As

Publication number Publication date
US20040259817A1 (en) 2004-12-23
CA2431834A1 (en) 2002-07-04
CA2431834C (en) 2009-11-24
EP1862167A2 (en) 2007-12-05
KR20040007427A (ko) 2004-01-24
WO2002051420A2 (en) 2002-07-04
DE60130147T2 (de) 2008-05-15
EP1862167A3 (en) 2009-04-29
EP1359920B1 (en) 2007-08-22
WO2002051420A3 (en) 2002-12-27
ATE370737T1 (de) 2007-09-15
ES2292637T3 (es) 2008-03-16
US20020107230A1 (en) 2002-08-08
MXPA03005741A (es) 2003-09-05
JP2004520320A (ja) 2004-07-08
DE60130147D1 (de) 2007-10-04
AU2002232759B2 (en) 2006-05-11
JP4945052B2 (ja) 2012-06-06
EP1359920A2 (en) 2003-11-12

Similar Documents

Publication Publication Date Title
KR100847346B1 (ko) 여성 성기능장애를 치료하기 위한 방법 및 제제
AU2002232759A1 (en) Methods and formulations for the treatment of female sexual dysfunction
US8076319B2 (en) Treatment of conditions relating to hormone deficiencies by administration of progestins
US10052386B2 (en) Progesterone formulations
KR100849919B1 (ko) 에스트로겐 대체 요법으로 치료중인 여성의 호르몬결핍증을 치료하기 위한 에스트로겐 및 안드로겐의 조합
MD3310346T2 (ro) Comprimată orodispersabilă ce conține estetrol
AU2003210757B2 (en) Method of hormonal therapy
MD3310345T2 (ro) Comprimată orodispersabilă ce conține estetrol
AU2003210759B2 (en) Step-down estrogen therapy
CN1672685A (zh) 一种新的避孕药物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130704

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20140704

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150715

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150715